Medical and Pharmaceutical Cizzle Biotechnology expands lung cancer blood biopsy test distribution into Caribbean This UK oncology company was spun out from the University of York's Department of Biology Rowan DunneDecember 16, 2024
Medical and Pharmaceutical Immutep starts multinational Phase III lung cancer drug trial at 150 sites It will examine the efficacy of 'eftilagimod alfa' in conjunction with Merck's Keytruda drug and chemo Rowan DunneDecember 12, 2024
Medical and Pharmaceutical University of Cambridge develops ‘zombie cell’ detecting lung cancer urine test It is not the first pee test used to help diagnose the disease, but it is the first of its kind Rowan DunneDecember 6, 2024
Health & Wellness BC woman advocates for lung cancer screening after shocking diagnosis at 39 Even if you have a healthy lifestyle and don't smoke you should still get checked out, she says Rowan DunneNovember 28, 2024
Medical and Pharmaceutical Kentucky governor recognizes Lung Cancer Awareness Month with formal proclamation Kentucky has the highest rate of the disease in the country, largely attributable to a vast number of smokers Rowan DunneNovember 26, 2024
Medical and Pharmaceutical GRAIL uses lung cancer blood test to determine who needs post-surgery therapy most The first patient has been screened with the R&D-stage test in a Phase III study Rowan DunneNovember 19, 2024
Medical and Pharmaceutical Korean consortium propels lung cancer drug development with AI, supercomputers It is being led by Seoul's bioscience company J INTS BIO Rowan DunneNovember 18, 2024
Medical and Pharmaceutical MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain This pharmaceutical company is also developing a synthetic cannabinoid drug to treat anxiety and cognitive decline Rowan DunneOctober 30, 2024
Medical and Pharmaceutical Ireland launches largest lung cancer research program to date This €4.9-million-euro initiative is being funded by the Irish Cancer Society Rowan DunneOctober 30, 2024
Medical and Pharmaceutical Biopharma operator Zai Lab surges to 16-month high on lung cancer drug trial results Analysts at Cantor Fitzgerald and JP Morgan Chase & Co recently gave the company an overweight rating Rowan DunneOctober 25, 2024